Radionuclide therapy for osseous metastases in prostate cancer

Seminars in Nuclear Medicine

Volumn 45, Issue 1, 2015, Pages 66-80

  Abi Ghanem, Alain S ^a   McGrath, Mary A ^a   Jacene, Heather A ^b  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; RADIUM CHLORIDE RA 223; RADIOPHARMACEUTICAL AGENT;

ANALGESIA; ANEMIA; BONE METASTASIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONFERENCE PAPER; DIARRHEA; DOSE RESPONSE; DOSIMETRY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG SAFETY; ELECTRON; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; LEUKOPENIA; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; QUALITY OF LIFE; RADIATION PROTECTION; RADIOISOTOPE THERAPY; THROMBOCYTOPENIA; ANIMAL; BONE NEOPLASMS; CLINICAL TRIAL (TOPIC); MALE; PATHOLOGY; PROCEDURES; PROSTATE TUMOR; SECONDARY; THERAPEUTIC USE;

ANIMALS; BETA PARTICLES; BONE NEOPLASMS; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RADIOTHERAPY;

EID: 84919432477     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2014.07.006     Document Type: Conference Paper

References (71)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 CA Cancer J Clin 64 1 2014 9 29
2. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2010. Bethesda, MD, National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975-2010/ based on November 2012 SEER data submission, posted to the SEER web site, April 2013
3. V. DePuy, K.J. Anstrom, and L.D. Castel Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer Support Care Cancer 15 7 2007 869 876
4. P.H. Lange, and R.L. Vessella Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone Cancer Metastasis Rev 17 4 1998 331 336
5. M.J. Lage, B.L. Barber, D.J. Harrison, and S. Jun The cost of treating skeletal-related events in patients with prostate cancer Am J Manag Care 14 5 2008 317 322
6. Cancer Pain Relief: With a Guide to Opioid Availability (ed 2) 1996 World Health Organization Geneva
7. R.A. Swarm, A.P. Abernethy, and D.L. Anghelescu Adult cancer pain J Natl Compr Canc Netw 11 8 2013 992 1022
8. E.B. Silberstein Systemic radiopharmaceutical therapy of painful osteoblastic metastases Semin Radiat Oncol 10 3 2000 240 249
9. F. Saad, D.M. Gleason, and R. Murray Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer J Natl Cancer Inst 96 11 2004 879 882
10. K. Fizazi, M. Carducci, and M. Smith Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study Lancet 377 9768 2011 813 822
11. D.R. Berthold, G.R. Pond, and F. Soban Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study J Clin Oncol 26 2 2008 242 245
12. I.F. Tannock, R. de Wit, and W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 15 2004 1502 1512
13. J.S. de Bono, C.J. Logothetis, and A. Molina Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 21 2011 1995 2005
14. J.S. de Bono, S. Oudard, and M. Ozguroglu Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial Lancet 376 9747 2010 1147 1154
15. P.W. Kantoff, C.S. Higano, and N.D. Shore Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 5 2010 411 422
16. C. Parker, S. Nilsson, and D. Heinrich Alpha emitter radium-223 and survival in metastatic prostate cancer N Engl J Med 369 3 2013 213 223
17. C.J. Ryan, M.R. Smith, and J.S. de Bono Abiraterone in metastatic prostate cancer without previous chemotherapy N Engl J Med 368 2 2013 138 148
18. H.I. Scher, K. Fizazi, and F. Saad Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 13 2012 1187 1197
19. K. Fizazi, H.I. Scher, and A. Molina Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study Lancet Oncol 13 10 2012 983 992
20. P.W. Kantoff, and J.L. Mohler New developments in the management of prostate cancer J Natl Compr Canc Netw 11 suppl 5 2013 653 657
21. J.L. Mohler, P.W. Kantoff, and A.J. Armstrong Prostate cancer, version 1.2014 J Natl Compr Canc Netw 11 12 2013 1471 1479
22. H.J. Biersack, H. Palmedo, and A. Andris Palliation and survival after repeated (188)Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: A retrospective analysis J Nucl Med 52 11 2011 1721 1726
23. A Chopra 177Lu-labeled methylene diphosphonate, in Molecular Imaging and Contrast Agent Database (MICAD) 2004-2013 National Center for Biotechnology Information Bethesda, MD Available at: http://www.ncbi.nlm.nih.gov/books/NBK56203
24. D.P. Joshi, W.H. Seery, L.G. Goldberg, and L. Goldman Evaluation of phosphorus 32 for intractable pain secondary to prostatic carcinoma metastases J Am Med Assoc 193 1965 621 623
25. P.G. Kluetz, W. Pierce, and V.E. Maher Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary Clin Cancer Res 20 1 2014 9 14
26. F.M. Paes, and A.N. Serafini Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain Semin Nucl Med 40 2 2010 89 104
27. A.T. Porter, A.J. McEwan, and J.E. Powe Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer Int J Radiat Oncol Biol Phys 25 5 1993 805 813
28. O. Sartor, R.H. Reid, and P.J. Hoskin Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer Urology 63 5 2004 940 945
29. S.C. Srivastava, H.L. Atkins, and G.T. Krishnamurthy Treatment of metastatic bone pain with tin-117m Stannic diethylenetriaminepentaacetic acid: A phase I/II clinical study Clin Cancer Res 4 1 1998 61 68
30. J. Yuan, C. Liu, and X. Liu Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: A phase II study Clin Nucl Med 38 2 2013 88 92
31. G. Henriksen, D.R. Fisher, and J.C. Roeske Targeting of osseous sites with alpha-emitting 223Ra: Comparison with the beta-emitter 89Sr in mice J Nucl Med 44 2 2003 252 259
32. H.A. Wright, J.L. Magee, and R.N. Hamm Calculations of physical and chemical reactions produced in irradiated water containing DNA Radiat Prot Dosimetry 13 1-4 1985 133 136
33. G. Kampf Induction of DNA double-strand breaks by ionizing radiation of different quality and their relevance for cell inactivation Radiobiol Radiother (Berl) 29 6 1988 631 658
34. M.R. Raju, Y. Eisen, S. Carpenter, and W.C. Inkret Radiobiology of alpha particles. III. Cell inactivation by alpha-particle traversals of the cell nucleus Radiat Res 128 2 1991 204 209
35. G. Sgouros, J.C. Roeske, and M.R. McDevitt MIRD pamphlet no. 22 (abridged): Radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy J Nucl Med 51 2 2010 311 328
36. G.E. Harrison, T.E. Carr, A. Sutton, and J. Rundo Plasma concentration and excretion of calcium-47, strontium-85, barium-133 and radium-223 following successive intravenous doses to a healthy man Nature 209 5022 1966 526 527
37. W.B. Looney, and V.E. Archer Radium inhalation accident; radium excretion study Am J Roentgenol Radium Ther Nucl Med 75 3 1956 548 558
38. J.A. Carrasquillo, J.A. O'Donoghue, and N. Pandit-Taskar Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer Eur J Nucl Med Mol Imaging 40 9 2013 1384 1393
39. S. Nilsson, R.H. Larsen, and S.D. Fosså First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases Clin Cancer Res 11 12 2005 4451 4459
40. M. Lassmann, and D. Nosske Dosimetry of 223Ra-chloride: Dose to normal organs and tissues Eur J Nucl Med Mol Imaging 40 2 2013 207 212
41. Xofigo® [product information]. Wayne, NJ, Bayer HealthCare Pharmaceuticals Inc, 2013
42. G. Henriksen, K. Breistøl, and S Bruland Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model Cancer Res 62 11 2002 3120 3125
43. O.S. Bruland, S. Nilsson, D.R. Fisher, and R.H. Larsen High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: Adjuvant or alternative to conventional modalities? Clin Cancer Res 12 20 Pt 2 2006 6250s 6257s
44. S. Nilsson, L. Balteskard, and S.D. Fossa Phase I study of AlpharadinTM (223Ra), an alpha-emitting bone-seeking agent in cancer patients with skeletal metastases. Oral presentation, Annual Congress of the EANM, Helsinki, September 8, 2004 Eur J Nucl Med Mol Imaging 31 S2 2004 290
45. S. Nilsson, L. Franzén, and C. Parker Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: A randomised, multicentre, placebo-controlled phase II study Lancet Oncol 8 7 2007 587 594
46. C.C. Parker, S. Pascoe, and A. Chodacki A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer Eur Urol 63 2 2013 189 197
47. A.J. Armstrong, and P.G. Febbo Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: An update and review of the literature Oncologist 14 8 2009 816 827
48. R.J. Cook, R. Coleman, and J. Brown Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer Clin Cancer Res 12 11 Pt 1 2006 3361 3367
49. M.R. Smith, R.J. Cook, and R. Coleman Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer Urology 70 2 2007 315 319
50. G. Sonpavde, G.R. Pond, and W.R. Berry Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy Urol Oncol 30 5 2012 607 613
51. S. Nilsson, P. Strang, and A.K. Aksnes A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer Eur J Cancer 48 5 2012 678 686
52. D.R. Berthold, G.R. Pond, and M. Roessner Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: Relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study Clin Cancer Res 14 9 2008 2763 2767
53. S. Nilsson, L. Franzén, and C. Parker Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases Clin Genitourin Cancer 11 1 2013 20 26
54. D. Cella, M.B. Nichol, and D. Eton Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy - Prostate: Results from a clinical trial of patients with metastatic hormone-refractory prostate cancer Value Health 12 1 2009 124 129
55. M.I. Suominen, J.P. Rissanen, and R. Käkönen Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis J Natl Cancer Inst 105 12 2013 908 916
56. G. Cook Jr, C. Parker, and S. Chua 18F-fluoride PET: Changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin) EJNMMI Res 1 1 2011 4
57. H.J. Biersack, S. Ezziddin, and F.F. Knapp Radium-223 in prostate cancer N Engl J Med 369 17 2013 1659
58. H. Palmedo, A. Manka-Waluch, and P. Albers Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: Randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate J Clin Oncol 21 15 2003 2869 2875
59. S.H. Han, J.M. de Klerk, and S. Tan The PLACORHEN study: A double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study J Nucl Med 43 9 2002 1150 1156
60. S. Smeland, B. Erikstein, and M. Aas Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: Results of a double-blind randomized study Int J Radiat Oncol Biol Phys 56 5 2003 1397 1404
61. R. Sciuto, A. Festa, and S. Rea Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: A randomized clinical trial J Nucl Med 43 1 2002 79 86
62. S.-M. Tu, R.E. Millikan, and B. Mengistu Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: A randomised phase II trial Lancet 357 9253 2001 336 341
63. I. Kuroda Strontium-89 for prostate cancer with bone metastases: The potential of cancer control and improvement of overall survival Ann Nucl Med 28 1 2014 11 16
64. G.O. Oosterhof, J.T. Roberts, and T.M. de Reijke Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: A phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group Eur Urol 44 5 2003 519 526
65. E. Borso, G. Boni, and I. Pastina Safety and antitumor efficacy of (153)Sm-EDTMP and docetaxel administered sequentially to patients with metastatic castration-resistant prostate cancer Nucl Med Commun 35 1 2014 88 94
66. K. Fizazi, P. Beuzeboc, and J. Lumbroso Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer J Clin Oncol 27 15 2009 2429 2435
67. S. Ricci, G. Boni, and I. Pastina Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer Eur J Nucl Med Mol Imaging 34 7 2007 1023 1030
68. O. Sartor, R.H. Reid, and D.L. Bushnell Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain Cancer 109 3 2007 637 643
69. V.J. Lewington Bone-seeking radionuclides for therapy J Nucl Med 46 suppl 1 2005 38S 47S
70. R.S. Hellman, and A.Z. Krasnow Radionuclide therapy for palliation of pain due to osteoblastic metastases J Palliat Med 1 3 1998 277 283
71. L. Bodei, M. Lam, and C. Chiesa EANM procedure guideline for treatment of refractory metastatic bone pain Eur J Nucl Med Mol Imaging 35 10 2008 1934 1940